mesna 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1711 3375-50-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mesna
  • mercaptoethanesulfonic acid
  • reduced coenzyme M
A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.
  • Molecular weight: 142.19
  • Formula: C2H6O3S2
  • CLOGP: -1.55
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 54.37
  • ALOGS: -1.05
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g Inhal.solution

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 28.13 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 62 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.65 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 20.50 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.36 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT1,FLT3,GRK2,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 65
kinase-selectivity-class ACVRL1,AURKA,AXL,BMX,BRAF,CDK1,CDK4,CDK9,DYRK1A,EPHB4,ERBB2,GRK2,IRAK1,IRAK3,MAP2K6,MAP3K21,MAPK7,PIK3CD,PIK3CG,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 25
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1988 FDA BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 1067.80 26.75 469 10296 157880 90459802
Encephalopathy 468.32 26.75 184 10581 46260 90571422
Mucosal inflammation 339.60 26.75 156 10609 57469 90560213
Pancytopenia 268.93 26.75 171 10594 120092 90497590
Neutropenia 255.46 26.75 212 10553 224692 90392990
Cystitis haemorrhagic 167.54 26.75 50 10715 5463 90612219
Pyrexia 156.61 26.75 280 10485 660205 89957477
Neurotoxicity 138.56 26.75 62 10703 21405 90596277
Thrombocytopenia 133.02 26.75 143 10622 208582 90409100
Leukopenia 112.06 26.75 94 10671 100616 90517066
Aplastic anaemia 107.49 26.75 45 10720 13224 90604458
Anaemia 105.13 26.75 166 10599 352636 90265046
Myelosuppression 104.39 26.75 70 10695 53521 90564161
Toxic encephalopathy 100.08 26.75 38 10727 8661 90609021
Febrile bone marrow aplasia 99.43 26.75 39 10726 9699 90607983
Cytokine release syndrome 91.71 26.75 51 10714 27922 90589760
Sepsis 72.94 26.75 98 10667 179716 90437966
Cytopenia 71.77 26.75 37 10728 17412 90600270
Haematotoxicity 70.78 26.75 33 10732 12502 90605180
Cytomegalovirus infection 69.89 26.75 42 10723 26560 90591122
Hypokalaemia 66.68 26.75 80 10685 131036 90486646
T-cell lymphoma refractory 61.08 26.75 10 10755 59 90617623
Myelodysplastic syndrome 60.14 26.75 35 10730 20868 90596814
Platelet count decreased 57.59 26.75 76 10689 136893 90480789
Arthralgia 56.27 26.75 12 10753 778510 89839172
Bone marrow failure 53.11 26.75 38 10727 32183 90585499
Thrombotic microangiopathy 52.40 26.75 29 10736 15714 90601968
Product use in unapproved indication 51.15 26.75 119 10646 336117 90281565
COVID-19 pneumonia 51.14 26.75 30 10735 18147 90599535
Disease progression 51.14 26.75 77 10688 156538 90461144
Venoocclusive liver disease 47.44 26.75 20 10745 5973 90611709
Neutrophil count decreased 47.19 26.75 50 10715 71482 90546200
White blood cell count decreased 46.03 26.75 76 10689 167033 90450649
Cardiotoxicity 43.54 26.75 23 10742 11366 90606316
Idiopathic pneumonia syndrome 42.35 26.75 10 10755 441 90617241
Acute polyneuropathy 42.13 26.75 10 10755 451 90617231
Hyperuricaemia 38.90 26.75 18 10747 6701 90610981
Peripheral swelling 37.78 26.75 3 10762 413103 90204579
Pneumothorax 37.21 26.75 25 10740 19142 90598540
Vena cava thrombosis 36.17 26.75 13 10752 2539 90615143
Drug ineffective 35.94 26.75 69 10696 1384229 89233453
Off label use 35.70 26.75 238 10527 1102014 89515668
Nasopharyngitis 34.48 26.75 4 10761 407100 90210582
Drug intolerance 34.18 26.75 6 10759 447585 90170097
Pain 34.17 26.75 41 10724 996300 89621382
Chronic hepatitis B 33.10 26.75 8 10757 390 90617292
Glomerulonephritis 32.83 26.75 12 10753 2458 90615224
Mitral valve disease 32.32 26.75 12 10753 2570 90615112
Polyneuropathy 32.30 26.75 23 10742 19318 90598364
Multiple organ dysfunction syndrome 31.96 26.75 40 10725 68296 90549386
Metastases to central nervous system 31.95 26.75 22 10743 17520 90600162
Enterobacter bacteraemia 31.77 26.75 9 10756 817 90616865
Fanconi syndrome 31.74 26.75 11 10754 1932 90615750
Posterior reversible encephalopathy syndrome 31.53 26.75 24 10741 22315 90595367
Aplasia 30.53 26.75 13 10752 3978 90613704
Hypocalcaemia 30.42 26.75 31 10734 42337 90575345
Ejection fraction decreased 30.18 26.75 25 10740 26228 90591454
Haematuria 29.63 26.75 28 10737 34909 90582773
Abdominal discomfort 29.45 26.75 10 10755 477318 90140364
Amniotic fluid index decreased 29.32 26.75 5 10760 39 90617643
BK polyomavirus test positive 28.40 26.75 6 10759 158 90617524
Septic shock 28.33 26.75 42 10723 84118 90533564
Hepatocellular injury 28.05 26.75 25 10740 28933 90588749
Peripheral sensory neuropathy 27.96 26.75 16 10749 9234 90608448
Mantle cell lymphoma recurrent 27.86 26.75 7 10758 401 90617281
Periorbital cellulitis 27.79 26.75 8 10757 769 90616913
Blood phosphorus decreased 27.64 26.75 13 10752 5021 90612661
Cancer fatigue 27.31 26.75 6 10759 191 90617491
Mental status changes 27.30 26.75 30 10735 44649 90573033
Systemic lupus erythematosus 27.30 26.75 5 10760 361891 90255791
Hypersensitivity 27.23 26.75 10 10755 454667 90163015
Hypoalbuminaemia 26.77 26.75 19 10746 15878 90601804

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 969.89 21.13 632 12198 185071 42423434
Encephalopathy 295.82 21.13 173 12657 41160 42567345
Cystitis haemorrhagic 167.50 21.13 68 12762 7261 42601244
Pyrexia 159.47 21.13 359 12471 393683 42214822
Neutropenia 148.32 21.13 236 12594 199195 42409310
Mucosal inflammation 139.68 21.13 117 12713 49257 42559248
Cytokine release syndrome 122.81 21.13 104 12726 44423 42564082
Myelosuppression 106.45 21.13 92 12738 40369 42568136
SARS-CoV-2 test negative 103.64 21.13 33 12797 1742 42606763
Venoocclusive liver disease 100.64 21.13 53 12777 10249 42598256
Anal inflammation 100.18 21.13 34 12796 2195 42606310
Proctalgia 94.37 21.13 45 12785 7048 42601457
Pancytopenia 90.97 21.13 142 12688 117601 42490904
Venoocclusive disease 88.32 21.13 36 12794 3879 42604626
Neutrophil count decreased 86.62 21.13 101 12729 63314 42545191
Aplastic anaemia 86.23 21.13 51 12779 12333 42596172
Aplasia 77.75 21.13 35 12795 4808 42603697
Fanconi syndrome 75.30 21.13 26 12804 1768 42606737
Accident 70.83 21.13 36 12794 6467 42602038
Febrile bone marrow aplasia 68.46 21.13 41 12789 10140 42598365
Foetal growth restriction 62.70 21.13 31 12799 5252 42603253
Haematotoxicity 60.59 21.13 39 12791 10946 42597559
Thrombocytopenia 57.96 21.13 156 12674 190123 42418382
Leukopenia 54.68 21.13 88 12742 74658 42533847
Haemorrhoids 53.49 21.13 43 12787 17054 42591451
Rectal abscess 50.04 21.13 19 12811 1696 42606809
Acute graft versus host disease 49.89 21.13 31 12799 8184 42600321
White blood cell count decreased 49.23 21.13 105 12725 110291 42498214
Stomatitis 47.86 21.13 67 12763 50262 42558243
Neurotoxicity 45.15 21.13 45 12785 23606 42584899
Platelet transfusion 43.13 21.13 17 12813 1677 42606828
Chronic graft versus host disease 42.42 21.13 25 12805 6000 42602505
Renal tubular disorder 41.63 21.13 23 12807 4886 42603619
Body temperature increased 39.35 21.13 39 12791 20319 42588186
Fall 39.29 21.13 11 12819 234509 42373996
Bone marrow failure 39.08 21.13 49 12781 33044 42575461
Vomiting 36.53 21.13 178 12652 289545 42318960
Anaemia 35.91 21.13 173 12657 280105 42328400
Staphylococcal bacteraemia 34.84 21.13 28 12802 11093 42597412
Death 34.09 21.13 56 12774 471129 42137376
Cystitis viral 33.51 21.13 13 12817 1229 42607276
Oesophagitis 32.83 21.13 31 12799 15216 42593289
Tumour compression 31.59 21.13 8 12822 182 42608323
Angiodysplasia 31.19 21.13 11 12819 796 42607709
Polyneuropathy 31.08 21.13 33 12797 18628 42589877
Drug ineffective 30.78 21.13 93 12737 630104 41978401
Hypoalbuminaemia 30.34 21.13 30 12800 15580 42592925
Immune effector cell-associated neurotoxicity syndrome 30.02 21.13 24 12806 9437 42599068
Chills 29.45 21.13 78 12752 93988 42514517
Low birth weight baby 28.95 21.13 24 12806 9931 42598574
Plasma cells decreased 28.28 21.13 6 12824 60 42608445
Neutropenic sepsis 27.98 21.13 29 12801 15917 42592588
Septic shock 27.67 21.13 75 12755 91597 42516908
Small for dates baby 27.34 21.13 18 12812 5245 42603260
Toxic encephalopathy 27.25 21.13 20 12810 6933 42601572
Fusarium infection 26.96 21.13 12 12818 1604 42606901
Myocardial infarction 26.81 21.13 3 12827 124006 42484499
Platelet count decreased 25.84 21.13 96 12734 138485 42470020
Engraftment syndrome 25.38 21.13 11 12819 1379 42607126
Herpes zoster reactivation 25.14 21.13 8 12822 421 42608084
Combined immunodeficiency 25.07 21.13 6 12824 107 42608398
Drug therapeutic incompatibility 24.66 21.13 6 12824 115 42608390
Plasmablast count increased 24.15 21.13 5 12825 44 42608461
B-lymphocyte count decreased 23.11 21.13 9 12821 860 42607645
Hypokalaemia 22.98 21.13 60 12770 71661 42536844
Malassezia infection 22.74 21.13 5 12825 60 42608445
Folliculitis 21.81 21.13 16 12814 5542 42602963
Fanconi syndrome acquired 21.21 21.13 11 12819 2059 42606446
Haemolytic anaemia 21.18 21.13 22 12808 12105 42596400

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 1926.57 22.95 1031 21162 315736 110251370
Encephalopathy 712.19 22.95 340 21853 80715 110486391
Mucosal inflammation 408.35 22.95 249 21944 95892 110471214
Pancytopenia 375.17 22.95 321 21872 209292 110357814
Neutropenia 356.38 22.95 406 21787 374214 110192892
Cystitis haemorrhagic 322.66 22.95 113 22080 12096 110555010
Pyrexia 297.29 22.95 593 21600 897672 109669434
Myelosuppression 205.17 22.95 162 22031 94178 110472928
Aplastic anaemia 195.11 22.95 96 22097 24212 110542894
Cytokine release syndrome 184.33 22.95 135 22058 70171 110496935
Febrile bone marrow aplasia 170.74 22.95 79 22114 17386 110549720
Thrombocytopenia 166.71 22.95 271 21922 348614 110218492
Pseudomonal sepsis 165.91 22.95 64 22129 8982 110558124
Secondary immunodeficiency 161.80 22.95 53 22140 4623 110562483
Neurotoxicity 155.52 22.95 100 22093 42107 110524999
Leukopenia 143.91 22.95 163 22030 148628 110418478
Venoocclusive liver disease 140.02 22.95 66 22127 15141 110551965
Anaemia 132.04 22.95 319 21874 546767 110020339
Haematotoxicity 130.76 22.95 70 22123 21012 110546094
SARS-CoV-2 test negative 128.12 22.95 37 22156 2116 110564990
Anal inflammation 118.43 22.95 36 22157 2460 110564646
Toxic encephalopathy 115.89 22.95 58 22135 15156 110551950
Neutrophil count decreased 114.39 22.95 131 22062 120810 110446296
Fanconi syndrome 114.19 22.95 38 22155 3481 110563625
White blood cell count decreased 106.45 22.95 176 22017 229214 110337892
Venoocclusive disease 102.63 22.95 41 22152 6309 110560797
Arthralgia 102.16 22.95 17 22176 779615 109787491
Aplasia 100.68 22.95 43 22150 7830 110559276
Bacterial infection 95.62 22.95 77 22116 45959 110521147
Proctalgia 90.79 22.95 47 22146 13175 110553931
Bone marrow failure 88.07 22.95 81 22112 57767 110509339
Mycobacterium chelonae infection 83.43 22.95 29 22164 3031 110564075
Lymphoid tissue hypoplasia 78.93 22.95 24 22169 1641 110565465
Thymus hypoplasia 78.62 22.95 24 22169 1663 110565443
Sepsis 77.83 22.95 190 22003 327156 110239950
Bronchopulmonary aspergillosis 77.44 22.95 57 22136 29806 110537300
Cytopenia 77.01 22.95 57 22136 30059 110537047
Hypokalaemia 76.68 22.95 134 22059 182314 110384792
Myelodysplastic syndrome 76.36 22.95 62 22131 37422 110529684
Cytomegalovirus viraemia 75.25 22.95 46 22147 17718 110549388
Drug ineffective 67.54 22.95 127 22066 1520413 109046693
Polyneuropathy 67.44 22.95 54 22139 31958 110535148
Platelet count decreased 67.17 22.95 145 22048 230298 110336808
Platelet transfusion 66.30 22.95 24 22169 2822 110564284
Accident 64.10 22.95 35 22158 10917 110556189
Acute graft versus host disease 64.08 22.95 37 22156 12844 110554262
Chronic graft versus host disease 60.32 22.95 32 22161 9425 110557681
Peripheral swelling 59.59 22.95 6 22187 404028 110163078
Hypoalbuminaemia 59.18 22.95 48 22145 28926 110538180
Viral infection 57.86 22.95 62 22131 53077 110514029
Septic shock 56.43 22.95 108 22085 157420 110409686
Renal tubular disorder 55.63 22.95 28 22165 7401 110559705
Drug hypersensitivity 54.94 22.95 12 22181 454078 110113028
Neutropenic sepsis 52.62 22.95 46 22147 30700 110536406
Cystitis viral 52.19 22.95 17 22176 1456 110565650
Off label use 51.05 22.95 491 21702 1499694 109067412
Fatigue 50.91 22.95 105 22088 1215853 109351253
T-cell lymphoma refractory 50.40 22.95 10 22183 109 110566997
Rectal abscess 49.16 22.95 19 22174 2677 110564429
Rhinovirus infection 48.59 22.95 30 22163 11759 110555347
Nasopharyngitis 46.54 22.95 11 22182 394350 110172756
Staphylococcal bacteraemia 45.87 22.95 33 22160 16655 110550451
Clostridium difficile colitis 45.77 22.95 50 22143 43728 110523378
Swelling 45.13 22.95 8 22185 351033 110216073
Haemorrhoids 44.92 22.95 45 22148 35627 110531479
Cytomegalovirus infection 44.86 22.95 55 22138 54389 110512717
Product use in unapproved indication 44.73 22.95 193 22000 447184 110119922
Fungal infection 44.60 22.95 53 22140 50753 110516353
Abdominal discomfort 44.52 22.95 12 22181 393846 110173260
Agranulocytosis 40.89 22.95 56 22137 61704 110505402
Weight increased 40.11 22.95 17 22176 419627 110147479
Immune effector cell-associated neurotoxicity syndrome 40.10 22.95 29 22164 14753 110552353
Posterior reversible encephalopathy syndrome 39.51 22.95 41 22152 33820 110533286
Acute kidney injury 38.94 22.95 239 21954 635191 109931915
Idiopathic pneumonia syndrome 38.71 22.95 12 22181 875 110566231
Contraindicated product administered 38.44 22.95 3 22190 248264 110318842
Cancer fatigue 38.43 22.95 10 22183 386 110566720
Fall 36.94 22.95 40 22153 603442 109963664
Drug intolerance 36.47 22.95 18 22175 406494 110160612
Enterobacter bacteraemia 36.34 22.95 13 22180 1477 110565629
Aspergillus infection 35.39 22.95 34 22159 25582 110541524
Thrombotic microangiopathy 35.29 22.95 36 22157 29113 110537993
Dizziness 33.85 22.95 55 22138 698138 109868968
Blood lactate dehydrogenase increased 33.67 22.95 43 22150 44291 110522815
Haematuria 33.59 22.95 60 22133 82945 110484161
Hypersensitivity 33.17 22.95 20 22173 403978 110163128
Pruritus 32.95 22.95 41 22152 581519 109985587
Enterobacter infection 32.43 22.95 18 22175 5793 110561313
Oesophagitis 32.13 22.95 34 22159 28681 110538425
Human bocavirus infection 31.95 22.95 11 22182 1117 110565989
Acute polyneuropathy 31.88 22.95 10 22183 758 110566348
Therapeutic product effect incomplete 31.28 22.95 4 22189 223801 110343305
Cystitis bacterial 30.82 22.95 11 22182 1242 110565864
Cardiotoxicity 30.39 22.95 26 22167 16855 110550251
Condition aggravated 30.20 22.95 64 22129 734772 109832334
Systemic lupus erythematosus 30.18 22.95 7 22186 254331 110312775
Tumour lysis syndrome 30.16 22.95 34 22159 30767 110536339
Rash 30.13 22.95 76 22117 820888 109746218
Pain in extremity 30.12 22.95 32 22161 487086 110080020
Inappropriate schedule of product administration 30.06 22.95 3 22190 203634 110363472
Disseminated aspergillosis 29.92 22.95 13 22180 2467 110564639
Norovirus test positive 29.59 22.95 10 22183 960 110566146
BK virus infection 29.51 22.95 23 22170 13083 110554023
Body temperature increased 29.48 22.95 45 22148 54668 110512438
Intentional product use issue 29.06 22.95 7 22186 247899 110319207
Angiodysplasia 28.87 22.95 11 22182 1491 110565615
Second primary malignancy 28.86 22.95 26 22167 18042 110549064
Muscle spasms 28.67 22.95 10 22183 278147 110288959
Peripheral sensory neuropathy 28.63 22.95 25 22168 16655 110550451
Wheezing 28.41 22.95 8 22185 255222 110311884
Sinusitis 28.37 22.95 12 22181 296676 110270430
Transfusion 28.22 22.95 30 22163 25442 110541664
Depersonalisation/derealisation disorder 28.18 22.95 12 22181 2169 110564937
Disease progression 28.07 22.95 110 22083 243924 110323182
Graft versus host disease 27.96 22.95 26 22167 18780 110548326
Lymphocyte count decreased 27.96 22.95 45 22148 57198 110509908
Asthma 27.57 22.95 8 22185 250283 110316823
Fanconi syndrome acquired 27.41 22.95 13 22180 3021 110564085
Amniotic fluid index decreased 27.31 22.95 5 22188 34 110567072
Acute graft versus host disease in skin 26.72 22.95 20 22173 10720 110556386
Viraemia 26.50 22.95 14 22179 4088 110563018
Chronic hepatitis B 26.14 22.95 8 22185 559 110566547
BK polyomavirus test positive 26.08 22.95 7 22186 305 110566801
Bacteraemia 25.92 22.95 37 22156 42353 110524753
Amniotic fluid volume decreased 25.86 22.95 7 22186 315 110566791
Fusarium infection 25.42 22.95 12 22181 2759 110564347
Mobility decreased 25.41 22.95 8 22185 237414 110329692
Drug therapeutic incompatibility 25.27 22.95 6 22187 158 110566948
Bacterial sepsis 25.02 22.95 19 22174 10407 110556699
Multiple organ dysfunction syndrome 24.94 22.95 77 22116 151633 110415473
Pneumothorax 24.89 22.95 33 22160 35252 110531854
Hypocalcaemia 24.86 22.95 46 22147 65320 110501786
Leukoencephalopathy 24.85 22.95 18 22175 9177 110557929
Contusion 24.73 22.95 8 22185 233353 110333753
Parainfluenzae virus infection 24.39 22.95 16 22177 6958 110560148
Foetal growth restriction 24.33 22.95 12 22181 3038 110564068
Ejection fraction decreased 24.00 22.95 35 22158 40845 110526261
Hyperbilirubinaemia 23.69 22.95 30 22163 30641 110536465
Malassezia infection 23.60 22.95 5 22188 77 110567029
Hepatic enzyme increased 23.50 22.95 18 22175 320874 110246232
Discomfort 23.40 22.95 7 22186 214700 110352406
Enterococcal sepsis 23.39 22.95 12 22181 3300 110563806
Urticaria 23.21 22.95 18 22175 318839 110248267
Face oedema 23.14 22.95 31 22162 33438 110533668

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R05CB05 RESPIRATORY SYSTEM
COUGH AND COLD PREPARATIONS
EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS
Mucolytics
ATC V03AF01 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Detoxifying agents for antineoplastic treatment
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:74518 anti-obesity agent
CHEBI has role CHEBI:75835 anti-anaemic agent
CHEBI has role CHEBI:231911 renoprotective agent
CHEBI has role CHEBI:233423 antifibrotic agent

Related Drugs by ATC class:

R05CB Mucolytics 13 drugs
acetylcysteineambroxolbromhexinecarbocisteinedomiodoldornase alfaeprazinoneerdosteineletosteinemannitolneltenexinesobrerol show all 13 →
V03AF Detoxifying agents for antineoplastic treatment 10 drugs
amifostineargininedexrazoxaneglucarpidaseleucovorinlevofolinic acidlysinepaliferminrasburicasetrilaciclib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Testicular Germ Cell Tumor indication
Prevention of Chemotherapy-Induced Hemorrhagic Cystitis indication
Ewing's sarcoma off-label use 76909002 DOID:3369
Burkitt's lymphoma off-label use 118617000
Non-small cell lung cancer off-label use 254637007 DOID:3908
Malignant tumor of head and/or neck off-label use 255056009
Osteosarcoma of bone off-label use 307576001 DOID:3376
Soft or Connective Tissue Sarcoma off-label use
Renal tubular acidosis contraindication 1776003 DOID:14219
Hyperbilirubinemia contraindication 14783006 DOID:2741
Dehydration contraindication 34095006
Fanconi syndrome contraindication 40488004 DOID:1062
Hypokalemia contraindication 43339004
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Kidney excision contraindication 108022006
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Impaired wound healing contraindication 271618001
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000
Coma contraindication 371632003
Impaired cognition contraindication 386806002
Breastfeeding (mother) contraindication 413712001
Cancer Chemotherapy Induced Hemorrhagic Cystitis contraindication
Polyneuropathies contraindication
Severe Bone Marrow Depression contraindication
Bone Metastases contraindication
CNS Toxicity contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.61 acidic
pKa2 9.77 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4019477 VUID
N0000147597 NUI
D01459 KEGG_DRUG
4019477 VANDF
C0000294 UMLSCUI
CHEBI:17905 CHEBI
CHEMBL975 ChEMBL_ID
D015080 MESH_DESCRIPTOR_UI
23662354 PUBCHEM_CID
2813 INN_ID
NR7O1405Q9 UNII
DB09110 DRUGBANK_ID
1546354 RXNORM
41498 MMSL
5057 MMSL
d01411 MMSL
002678 NDDF
108821000 SNOMEDCT_US
386922000 SNOMEDCT_US
COM PDB_CHEM_ID
19767-45-4 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
mesna HUMAN PRESCRIPTION DRUG LABEL 1 0143-9260 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 25 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1305 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 27 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1305 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 27 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1307 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 24 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1307 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 24 sections
MESNA HUMAN PRESCRIPTION DRUG LABEL 1 10019-951 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 26 sections
MESNA HUMAN PRESCRIPTION DRUG LABEL 1 10019-951 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 26 sections
MESNA HUMAN PRESCRIPTION DRUG LABEL 1 10019-953 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 26 sections
MESNA HUMAN PRESCRIPTION DRUG LABEL 1 10019-953 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 26 sections
Mesna HUMAN PRESCRIPTION DRUG LABEL 1 25021-201 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
MESNA HUMAN PRESCRIPTION DRUG LABEL 1 50742-354 TABLET, FILM COATED 400 mg ORAL ANDA 29 sections
MESNA Human Prescription Drug Label 1 55150-520 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 25 sections
Mesna HUMAN PRESCRIPTION DRUG LABEL 1 63323-733 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 27 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 67108-3565 TABLET, FILM COATED 400 mg ORAL NDA 26 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 67108-3565 TABLET, FILM COATED 400 mg ORAL NDA 26 sections
Mesna Human Prescription Drug Label 1 68083-161 SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 83703-559 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 27 sections